Since dyslipidemia accounts for more than 50% of the population-attributable risk for the onset of CAD, indicating the remodeled CAD risk induced by adiponectin variants may originate from a remodeled lipid profile. This evidence concerns the gene ADIPOQ and metabolic syndrome.